Skip to main content
Top
Published in: Indian Journal of Hematology and Blood Transfusion 2/2015

01-06-2015 | Original Article

Novel Βeta (β)-Thalassemia Mutation in Turkish Children

Authors: Mustafa Ulasli, Serdar Oztuzcu, Sevil Kirkbes, Ali Bay, Yusuf Ziya Igci, Recep Bayraktar, Mehri Igci, Sercan Ergun, Ecir Ali Cakmak, Elif Aytekin, Ahmet Arslan

Published in: Indian Journal of Hematology and Blood Transfusion | Issue 2/2015

Login to get access

Abstract

Beta (β)-thalassemia is the most frequently observed hereditary blood disorder in the world. It is characterized by deficiency of hemoglobin β-globin gene and is also a profoundly heterogeneous both at the molecular and clinical level. In the case of β-thalassemia, there is reduced (β+ type) or absent (βo type) synthesis of the beta chains of hemoglobin. β-Thalassemia clinically occurs in three main forms: major, intermedia and minor according to requirement of transfusion. The objective of this study was to evaluate β-thalassemia mutations in 89 patients ranging from 2 months to 16 years of age, who enrolled to Medical School Research and Training Hospital, Gaziantep University. The direct DNA sequence analysis was performed for mutation scanning of β-globin gene. 89 children with β-Thalassemia including all types were analyzed, 16 different β-thalassemia mutations were detected. We have also identified a novel mutation (HBB.c.-80delT, rs397509430) in the promoter region (−30 TATA box) of β-globin gene, and clinical data of patient having novel mutation was given. The β-Thalassemia mutations were determined as β-Thalassemia major type in 42 patients (47.19 %), β-Thalassemia intermedia in 4 (4.49 %), β-Thalassemia minor in 43, (48.31 %) patients. The most frequent mutation was IVS I-110 G>A, followed by IVS I-1 G>A, IVS I-6 T>C, IVS II-1 G>A, respectively.
Literature
4.
go back to reference Marengo-Rowe AJ (2007) The thalassemias and related disorders. Proc (Bayl Univ Med Cent) 20(1):27–31 Marengo-Rowe AJ (2007) The thalassemias and related disorders. Proc (Bayl Univ Med Cent) 20(1):27–31
7.
go back to reference Thein SL (2005) Genetic modifiers of beta-thalassemia. Haematologica 90(5):649–660PubMed Thein SL (2005) Genetic modifiers of beta-thalassemia. Haematologica 90(5):649–660PubMed
9.
go back to reference Dean A (2004) Chromatin remodelling and the interaction between enhancers and promoters in the beta-globin locus. Brief Funct Genomic Proteomic 2(4):344–354CrossRefPubMed Dean A (2004) Chromatin remodelling and the interaction between enhancers and promoters in the beta-globin locus. Brief Funct Genomic Proteomic 2(4):344–354CrossRefPubMed
12.
go back to reference Aksoy M, Kutlar A, Kutlar F, Dincol G, Erdem S, Bastesbihci S (1985) Survey on haemoglobin variants, beta thalassaemia, glucose-6-phosphate dehydrogenase deficiency, and haptoglobin types in Turks from western Thrace. J Med Genet 22(4):288–290CrossRefPubMedCentralPubMed Aksoy M, Kutlar A, Kutlar F, Dincol G, Erdem S, Bastesbihci S (1985) Survey on haemoglobin variants, beta thalassaemia, glucose-6-phosphate dehydrogenase deficiency, and haptoglobin types in Turks from western Thrace. J Med Genet 22(4):288–290CrossRefPubMedCentralPubMed
14.
15.
go back to reference Altay C (2002) The frequency and distribution pattern of β–thalassaemia mutations in turkey. Turkish J Hematology 19:309–324 Altay C (2002) The frequency and distribution pattern of β–thalassaemia mutations in turkey. Turkish J Hematology 19:309–324
Metadata
Title
Novel Βeta (β)-Thalassemia Mutation in Turkish Children
Authors
Mustafa Ulasli
Serdar Oztuzcu
Sevil Kirkbes
Ali Bay
Yusuf Ziya Igci
Recep Bayraktar
Mehri Igci
Sercan Ergun
Ecir Ali Cakmak
Elif Aytekin
Ahmet Arslan
Publication date
01-06-2015
Publisher
Springer India
Published in
Indian Journal of Hematology and Blood Transfusion / Issue 2/2015
Print ISSN: 0971-4502
Electronic ISSN: 0974-0449
DOI
https://doi.org/10.1007/s12288-014-0380-6

Other articles of this Issue 2/2015

Indian Journal of Hematology and Blood Transfusion 2/2015 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine